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A B S T R A C T   
Subtle blood–brain barrier (BBB) permeability increases have been shown in small vessel disease (SVD) using 
various analysis methods. Following recent consensus recommendations, we used Patlak tracer kinetic analysis, 
considered optimal in low permeability states, to quantify permeability-surface area product (PS), a BBB leakage 
estimate, and blood plasma volume (vP) in 201 patients with SVD who underwent dynamic contrast-enhanced 
MRI scans. We ran multivariable regression models with a quantitative or qualitative metric of white matter 
hyperintensity (WMH) severity, demographic and vascular risk factors. PS increased with WMH severity in grey 
(B = 0.15, Confidence Interval (CI): [0.001,0.299], p = 0.049) and normal-appearing white matter (B = 0.015, 
CI: [− 0.008,0.308], p = 0.062). Patients with more severe WMH had lower vP in WMH (B = -0.088, CI: [− 0.138,- 
0.039], p < 0.001), but higher vP in normal-appearing white matter (B = 0.031, CI: [− 0.004,0.065], p = 0.082). 
PS and vP were lower at older ages in WMH, grey and white matter. We conclude higher PS in normal-appearing 
tissue with more severe WMH suggests impaired BBB integrity beyond visible lesions indicating that the 
microvasculature is compromised in normal-appearing white matter and WMH. BBB dysfunction is an important 
mechanism in SVD, but associations with clinical variables are complex and underlying damage affecting 
vascular surface area may alter interpretation of tracer kinetic results.   
1. Introduction 
Cerebral small vessel disease (SVD) is an underlying cause in about 
25% of strokes and up to 50% of dementias (alone or in combination 
with Alzheimer’s disease (AD)) (Wardlaw et al., 2019). The effects of 
SVD on the brain appear as several types of lesions visible on structural 
MRI, the commonest of which are white matter hyperintensities (WMH) 
(Wardlaw et al., 2019; Wardlaw et al., 2013). 
The vascular dysfunction that leads to SVD brain damage is poorly 
understood, but dysfunction of the blood–brain barrier (BBB) has been 
proposed. Various components of BBB dysfunction may cause brain 
damage including leakage of fluids, proteins and fibrinogen into the 
vessel walls and perivascular tissues which could lead to thickening and 
stiffening of the arteriole wall, which may in turn reduce vasoreactivity, 
oxygen and essential nutrient transport, plus perivascular oedema and 
inflammation (Wardlaw et al., 2019). BBB leakiness increases subtly 
with normal ageing (Erdo et al., 2017; Farrall and Wardlaw, 2009), but 
has also been found in patients with Alzheimer’s disease and in patients 
with small vessel (lacunar) stroke; leakage was worse in patients with 
more WMH, and, specifically, worse in WMH (Li et al., 2017; Wardlaw 
et al., 2017; Zhang et al., 2017). Subtle BBB leakiness may also lead to 
hippocampal damage and cognitive decline after stroke and in patients 
at risk of AD (Li et al., 2017; Li et al., 2018; Montagne et al., 2020; 
Nation et al., 2019; Sweeney et al., 2018; Wardlaw et al., 2017; Zhang 
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et al., 2017). 
Several methods have been proposed to evaluate BBB permeability in 
people, with dynamic contrast-enhanced MRI (DCE-MRI) being most 
widely used for quantification in vivo (Thrippleton et al., 2019). DCE- 
MRI exploits the paramagnetic properties of gadolinium-based 
contrast agents to track T1-weighted signal enhancement over time to 
assess the intra- and extra-vascular distribution of the tracer. Multiple 
analytical approaches have been employed to measure these changes, 
however recent literature and recommendations (Raja et al., 2018; 
Thrippleton et al., 2019) have converged on tracer kinetic modelling to 
estimate the vascular permeability-surface area product (PS) as an es-
timate of BBB leakage in a given region of interest. This method 
simultaneously calculates plasma volume fraction (vP) in the same re-
gion of interest. These two values together provide complementary 
measures of key aspects of vascular dysfunction at tissue level. 
Previously, we used a semi-quantitative approach with linear mixed 
modelling of the signal enhancement slopes to compare relative leakage 
between tissues, by SVD and patient characteristics, but did not calcu-
late an individual patient or tissue quantitative leakage parameter 
(Wardlaw et al., 2017). We identified higher leakage in WMH than in 
normal appearing white matter, with leakage in normal appearing white 
matter also increasing with proximity to WMH and with WMH burden 
(Wardlaw et al., 2017). While semi-quantitative approaches can be 
implemented easily, they do not provide quantitative markers of BBB 
leakage, limiting direct comparisons between subjects and studies 
(Thrippleton et al., 2019). We therefore set out to re-analyse the data 
using the potentially more sensitive and specific method of tracer kinetic 
analysis to confirm the previous findings. 
In this work, we performed tracer kinetic modelling according to 
recent consensus recommendations (Thrippleton et al., 2019), analysed 
since the original semi-quantitative results were published from the 
same dataset (Wardlaw et al., 2017), and assessed associations between 
disease related and demographic variables with PS and vP in grey matter, 
white matter, WMH and recent stroke lesions. We hypothesised that PS 
in grey matter, white matter and WMH would increase with WMH 
burden, and that vP would correspondingly decrease in WMH and sur-
rounding healthy tissue due to impaired cerebral blood flow. 
2. Methods 
2.1. Recruitment 
The inclusion criteria, participant recruitment, medical assessment 
and MRI acquisition have been published in detail previously (Heye 
et al., 2016; Valdes Hernandez et al., 2015; Wardlaw et al., 2017). 
Briefly, the patients were recruited prospectively with their first clini-
cally evident mild (non-disabling) ischaemic stroke. Patients were only 
eligible for inclusion where they had a confirmed diagnosis of ischaemic 
stroke, capacity to consent, were aged over 18 years and willing to un-
dergo a baseline MRI scan followed by DCE-MRI 1 to 3 months post- 
stroke. Medical history was obtained by a stroke physician. Stroke 
subtype (lacunar or cortical) was determined by a panel of stroke experts 
based on clinical and MRI features (Wardlaw et al., 2017). The study was 
approved by the Lothian Ethics of Medical Research Committee (REC 
09/81101/54) and NHS Lothian R&D Office (2009/W/NEU/14) and all 
patients gave written informed consent. The study was conducted in full 
conformity with the Declaration of Helsinki. 
2.2. MRI protocol 
As previously published (Valdes Hernandez et al., 2015), we per-
formed MRI on a 1.5T GE Signa HDxt scanner with an 8-channel phased 
array head-coil, and acquired T1-weighted, T2-weighted, FLAIR, 
gradient echo and diffusion tensor images (Wardlaw et al., 2013). We 
performed DCE-MRI (Heye et al., 2016) at 1–3 months after stroke to 
avoid the acute effects of the index stroke on the BBB. Pre-contrast T1 
(T10) maps were generated from two 3D T1-weighted fast-spoiled 
gradient-echo (FSPGR) acquisitions with flip angles of 2 and 12◦ (TR/TE 
= 8.24/3.1 ms, 24x24cm FOV, 256 × 192 acquisition matrix and 42 × 4 
mm thick slices). A 0.2 ml/kg (i.e., 0.1 mmol/kg body weight) dose of 
Gadoterate meglumine (Gd-DOTA, DOTAREM; Guerbet, Paris, France) 
was injected intravenously at 2 ml/second via an injection pump. The 
3D T1-weighted sequence (flip angle = 12◦) was then repeated 20 times 
sequentially for c.24 min with a temporal resolution of around 73 s, 
employing a long acquisition time to detect subtle BBB leaks (Wardlaw 
et al., 2017). 
2.3. Image analysis 
An expert neuroradiologist used validated visual scores to quantify 
WMH (Fazekas score), other SVD features (lacunes, perivascular spaces, 
microbleeds, brain atrophy), the recent ‘index’ lacunar or cortical infarct 
and any old infarcts. We registered structural images to the first pre- 
contrast FSPGR-12◦ scan (Jenkinson and Smith, 2001). We generated 
masks for the intracranial volume, cerebrospinal fluid (CSF), WMH and 
normal-appearing WM using a validated multispectral method (Valdes 
Hernandez et al., 2010) before manual editing to remove incorrectly 
classified tissue. We computationally generated subcortical/deep grey 
matter masks (Heye et al., 2016). We defined the recent ‘index’ stroke 
lesion as hyperintense on the diffusion weighted image obtained at 
diagnosis, including corresponding signal changes on other sequences, 
and manually masked the lesion using Analyze 11.0 (AnalyzeDirect). 
2.4. Tracer kinetic modelling 
The analysis procedure for the DCE-MRI data was as described in 
Heye et al (Heye et al., 2016) except that fitting to the Patlak model was 
implemented via a multiple linear regression approach, and in line with 
recent consensus recommendations (Thrippleton et al., 2019). We 
applied modelling in regions of interest for each of four tissue classes: 
normal appearing white matter (WM), deep grey matter (GM), white 
matter hyperintensities (WMH) and recent stroke lesions (RSL). In brief, 
we calculated the median signal intensity (Si) across all voxels within 
each tissue mask and measured signal enhancement (Ei) relative to the 
corresponding pre-contrast signal intensity (S0) as Ei=(Si-S0)/S0. We 
generated T1 maps using the variable flip angle method (Brookes et al., 
1999) before calculating the contrast agent concentration, Ci, as in 
Armitage et al (Armitage et al., 2005). We determined the vascular input 
function by manually selecting voxels in the superior sagittal sinus and 
converted the measured whole-blood concentration Cb(t) to blood 
plasma concentration Cp(t) using individual haematocrit values as pre-
viously described (Heye et al., 2016). 
We applied the Patlak model to fit the concentration of contrast 
agent in the tissue, Ct(t), using publicly available in-house software 
(https://github.com/mjt320/DCE-functions) programmed in MATLAB 
(MathWorks, Natick, MA, USA), as this model has been shown to be most 
appropriate for assessing low-permeability tissue at low temporal reso-
lution (Barnes et al., 2016; Cramer and Larsson, 2014; Heye et al., 2016), 
to obtain values for the fractional plasma volume (vp, 10− 2) and 
permeability surface area product (PS, 10− 4 min− 1). We reported 
leakage results as estimated PS instead of the alternative volume transfer 
constant, KTrans symbol, which represents the rate of transport of GBCA 
from arterial blood plasma to the EES; provided early data points are 
excluded from the analysis (as here) and the Patlak model assumptions 
are valid (as previously demonstrated (Barnes et al., 2016; Cramer and 
Larsson, 2014; Heye et al., 2016)), the arterial, capillary and venous 
GBCA blood plasma concentrations are similar and KTrans≈PS. For 
comparison we also reported the signal enhancement slopes (signal in-
tensity change per unit time) previously calculated in the same dataset 
(Munoz Maniega et al., 2017). 
M.S. Stringer et al.                                                                                                                                                                                                                              
NeuroImage: Clinical 32 (2021) 102883
3
2.5. Statistics 
We constructed multiple linear regression models in R (v3.6.3) to 
explore the relationship between the permeability surface area (PS), 
fractional plasma volume (vP) and WMH burden (assessed as a) Fazekas 
score (0–6, summing the deep and periventricular white matter com-
ponents) and b) WMH volume normalised to the intracranial volume in 
separate models), accounting for age, stroke subtype (cortical (0) vs 
lacunar (1)), mean arterial blood pressure, hypertension diagnosis 
(diagnosed (1), not diagnosis (0)), pulse pressure and smoking status 
(current/stopped within last year (1), never/stopped over a year (0)) to 
control for key vascular risk factors and for consistency with the previ-
ous semi-quantitative analysis (Wardlaw et al., 2017). We included re-
sults for models including Fazekas score and WMH volume normalised 
to the intracranial volume, as while highly correlated visual and 
computational measures of WMH severity differ (Valdes Hernandez 
et al., 2013), they may provide complementary information. We 
checked normality of residuals and homogeneity of variance using Q-Q 
plots, histograms and plots of residuals vs fitted values for each model. 
We checked variance inflation factors for each model to avoid multi- 
collinearity. 
To explore whether observed associations may have been influenced 
by differences in the vascular input function associated with age or 
WMH burden, we dichotomised by median Fazekas score (3) for high 
(>=4)/low (<=3) Fazekas score and above/below median age (66.72 
years). We assessed the peak and slope of the Gd-time curves by plotting 
the mean vascular input function and Gd concentration over time in 
each tissue type, including indicators of standard mean errors and 
standard deviation. 
3. Results 
DCE-MRI data suitable for analysis were obtained in 201 patients, 
with a median age of 66.8 (Interquartile range: 56.8–75.2) years, on 
average 38 days after stroke. Key demographic and clinical parameters 
are provided in Table 1 along with summary statistics for the DCE-MRI 
parameters. PS was highest in recent stroke lesions, followed by WMH, 
GM and WM. Variance inflation factors were below 2 for all included 
variables in each model. 
3.1. Associations between tracer kinetic parameters, clinical and SVD 
imaging variables 
PS decreased with age in WM (B = -0.044, CI: [− 0.07, − 0.018]), GM 
(B = -0.044, CI: [− 0.068, − 0.019]) and WMH (B = -0.03, CI: [− 0.058, 
− 0.002]) but not in the recent infarct (B = 0.019, CI: [− 0.067, 0.105]). 
There was no association of PS with hypertension or smoking in GM, 
WM or WMH (Table 2, Supplementary Table 1), but PS was higher in the 
recent infarct in patients with versus without hypertension (B = 2.195, 
CI: [0.194, 4.197]). 
PS increased with the severity of WMH (degree of white matter 
injury) in GM (B = 0.150, CI: [0.001, − 0.299]) with a trend in WM (B =
0.150, CI: [− 0.008, 0.308]) but not in WMH (B = 0.092, CI: [− 0.081, 
0.265]) or in the recent infarct (B = -0.067, CI: [− 0.596, 0.461]) (Fig. 1). 
Associations were stronger for WMH severity expressed as Fazekas score 
than for WMH volume (Table 2, Supplementary Table 1). Also, PS was 
higher in recent cortical than lacunar infarcts (B = -2.017, CI: [− 3.621, 
− 0.413]). 
vP decreased with age in WM (B = -0.008, CI: [− 0.013, − 0.002]), GM 
(B = -0.007, CI: [− 0.014, − 0.001]), and WMH (B = -0.008, CI: [− 0.016, 
0.000]) but not in the recent infarct (B = -0.001, CI: [− 0.012, 0.010]) 
(Table 3, Supplementary Table 2). Additionally, vP declined with hy-
pertension in GM (B = -0.145, CI: [− 0.279, − 0.012]) and WM (B =
-0.162, CI: [− 0.283, − 0.040]) and with smoking in GM (B = -0.131, CI: 
[− 0.256, − 0.006]). 
vP declined with increasing WMH severity in WMH (B = -0.088, CI: 
[− 0.138, − 0.039]) but increased in WM (B = 0.031, CI: [− 0.004, 
0.065]), no effect was present in GM (B = 0.010, CI: [− 0.028, 0.058]) or 
the recent infarct (B = -0.026, CI: [− 0.093, 0.041]) (Table 3, Supple-
mentary Table 2, Fig. 1). The associations were stronger for WMH 
severity expressed as volume than for Fazekas score in WM and GM but 
in WMH associations were stronger for Fazekas score than volume 
(Table 3, Supplementary Table 2). There was no association between vP 
and vascular risk factors in the recent infarct (Table 3, Supplementary 
Table 2). 
3.2. Impact of age and WMH severity on vascular input functions and 
tissue concentration curves 
When dichotomised by median age, Gadolinium concentration 
measured in blood (i.e. the vascular input function) was slightly higher 
in the younger patient group after the bolus peak; dichotomising by 
Fazekas scores showed only a marginal difference at the four timepoints 
immediately after the bolus peak (Fig. 2a). Fig. 2b shows that in younger 
versus older patients, the Gadolinium concentration peak was higher and 
the curve thereafter remained higher in GM, WM and WMH, with 
generally clear separation of the outer bounds of the standard mean 
error (Fig. 2b), with no difference in the recent infarct. The slopes of the 
mean tissue concentration curves were greatest in recent infarcts 
(consistent with BBB leakage) followed by WMH, then WM and GM, and 
were similar for the younger and older patients. In patients with higher 
versus lower Fazekas scores, tracer concentration peak was lower, but 
the subsequent slope was greater in WMH. There was no apparent dif-
ference between the peak of the curves by Fazekas score in GM, WM or 
recent infarcts, but the slope was steepest in recent infarcts followed by 
WMH in patients with Fazekas score ≥ 4, WM, WMH in patients with 
Fazekas score ≤ 3 and GM, similar to the analysis dichotomised by pa-
tient age. 
Table 1 
Patient demographics of the 201 patients with DCE-MRI data. Categorical data 
are presented as n (%), for continuous variables mean (standard deviation) is 
given unless specified. IQR = Inter-quartile range.  
Demographic/clinical risk factors 
Age (IQR) 66.7 (56.8–75.2) 
Stroke subtype Lacunar 92 (45.8%) 
Cortical 109 (54.2%) 
Mean arterial pressure median (IQR) 141 (130–159) 
Hypertension 150 (73.1%) 
Pulse pressure median (IQR) 60 (49–76) 
Smoking status (current or stopped in last year) 72 (35.8%)  
White matter burden parameters 
Fazekas score 0 7 (3.4%) 
1 17 (8.5%) 
2 74 (36.8%) 
3 23 (11.4%) 
4 29 (14.4%) 
5 20 (10.0%) 
6 31 (15.4%) 
% WMH in intracranial volume, median (IQR) 0.91 (0.31–2.36)  
DCE-MRI parameters (PS: 10− 4 min− 1, vP: 10− 2, Signal enhancement slope: % min− 1) 
Deep grey matter PS 3.896 (1.588) 
vP 1.232 (0.406) 
Signal enhancement slope 0.00533 (0.05096) 
Normal-appearing white matter PS 2.929 (1.672) 
vP 0.600 (0.370) 
Signal enhancement slope 0.02215 (0.03969) 
White matter hyperintensities PS 3.941 (1.775) 
vP 0.825 (0.560) 
Signal enhancement slope 0.03107 (0.05564) 
Recent stroke lesions PS 5.714 (4.700) 
vP 0.815 (0.584) 
Signal enhancement slope 0.08518 (0.11335)  
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4. Discussion 
We show that PS, a quantitative measure of BBB leakage, increases 
with WMH severity in GM and normal-appearing WM, but not WMH, 
independent of key risk factors. Mean PS was highest in stroke lesions, 
followed by WMH, GM and WM. With increasing WMH severity vP de-
clines in WMH and increases in WM, but not GM. The strength of as-
sociation varied between the different tissues sampled and whether the 
WMH were quantified by visual score or volume, although the overall 
pattern was consistent. Both PS and vP decreased with age in GM, WM 
and WMH consistent with loss of small vessels at older ages. 
4.1. Comparison to semi-quantitative analysis 
As in the previously reported analysis using a semi-quantitative BBB 
leakage parameter (Wardlaw et al., 2017), we found increased PS with 
WMH severity in GM and WM. Previously, we also found increased 
leakage in WMH with increasing WMH severity, consistent with the 
observation of a steeper slope of the Gd-enhancement curve in patients 
with severe vs milder WMH (Fig. 2b). While the tracer kinetic analysis 
found PS in WMH was higher with worse WMH severity the effect was 
not significant after correcting for other key variables. In recent stroke 
lesions, we find PS was greater in cortical than lacunar infarcts and 
increased with hypertension. By contrast PS and vP decreased with age in 
WM, GM and WMH, and associations with PS were generally weaker 
than in the previous analysis. We found vP decreased with hypertension 
in GM, WM and WMH, but not recent stroke lesions. In the semi- 
quantitative analysis, leakage increased in GM, WM and WMH with 
hypertension. Although vP decreased with smoking in GM, no compa-
rable association was revealed by the semi-quantitative analysis. 
Subject-specific PS and semi-quantitative leakage estimates showed a 
broadly linear relationship (Supplementary Fig. 1), reflecting previous 
simulation results (Heye et al., 2016). Both approaches identified the 
highest leakage rates in recent stroke lesions, followed by WMH and 
WM. However, while GM had the lowest enhancement slope of all the 
tissues, PS values in GM were higher than in WM and similar to those in 
WMH. As enhancement slope is not a direct measure of BBB leakage, 
being influenced by multiple factors including vP (Heye et al., 2016), 
such inconsistencies are expected. 
4.2. Associations between tracer kinetic parameters and WMH severity 
As we previously reported, PS and vP are higher in WMH than WM 
(Heye et al., 2016), so increases in PS and vP with WMH severity in 
normal appearing tissue may suggest apparently healthy tissue is also 
compromised. This could result from global changes affecting vessel 
health or as a prelude to further WMH evolution (Alber et al., 2019; 
Brown and Thore, 2011), consistent with DTI data from other studies 
(Munoz Maniega et al., 2017). Impaired blood flow, increased blood 
volume and delayed transit times have been reported previously in 
WMH (Arba et al., 2017; Ostergaard et al., 2016). Cerebral blood flow 
might increase in early disease stages to compensate for reduced oxygen 
extraction efficacy (Ostergaard et al., 2016). Hypoxia in compromised 
but still normal appearing tissue may therefore lead to higher vP due to 
increased blood volume in dilated arterioles or venules (Zhang et al., 
2020) also interpreted as dysfunctional blood flow (Bailey et al., 2004). 
Meanwhile, as vascular surface area and cerebral blood volume scale 
with vessel density (Varatharaj et al., 2019), vP in WMH decreasing with 
WMH severity would be consistent with fewer blood vessels in damaged 
tissue as WMH severity increases. Hence, both findings would further 
support the role of BBB dysfunction in SVD even beyond visibly 
damaged tissue. 
Several papers have also found permeability increased with disease 
severity in normal appearing tissues (Li et al., 2017; Topakian et al., 
2010; Wardlaw et al., 2017), but fewer explore associations between 
disease burden and permeability metrics using quantitative techniques 
while correcting for key covariates (Li et al., 2017; Li et al., 2018; Taheri 
et al., 2011; Thrippleton et al., 2019). Li et al found KTrans increased with 
WMH severity (Li et al., 2017) and total SVD score (Li et al., 2018) in 
GM, WM and WMH while vP decreased with WMH severity in GM, WM 
and WMH (Li et al., 2017) when adjusted for age, sex, and vascular risk 
factors, but excluded symptomatic stroke patients. Zhang et al reported 
decreased permeability (Ki) in WMH with increasing WMH severity but 
found no associations in GM and WM (Zhang et al., 2019) adjusting for 
age and sex, but not vascular risk factors. Comparing patients to age 
matched controls, van de Haar et al found higher Ki in GM and lower vP 
Table 2 
Permeability surface area (PS, 10− 4 min− 1) against age (years), Fazekas score, 
stroke subtype, mean arterial pressure (mmHg), hypertension status, pulse 
pressure (mmHg) and smoking status in each tissue type of interest. (WM =
white matter, CI = confidence interval, MAP = mean arterial pressure).   
Tissue PS associations using Fazekas score 
Tissue Variable B 
coefficient 
95% CI p-value 
Normal appearing 
WM 
Age − 0.044 − 0.070 to 
− 0.018  
<0.001  





− 0.398 − 0.868 to 
0.072  
0.097  
MAP − 0.006 − 0.023 to 
0.011  
0.500  
Hypertension 0.411 − 0.141 to 
0.963  
0.144  










Age − 0.030 − 0.058 to 
− 0.002  
0.035  





− 0.039 − 0.550 to 
0.473  
0.882  
MAP 0.002 − 0.017 to 
0.021  
0.862  
Hypertension 0.309 − 0.294 to 
0.912  
0.314  





− 0.028 − 0.594 to 
0.537  
0.922 
Grey matter Age − 0.044 − 0.068 to 
− 0.019  
<0.001  





− 0.285 − 0.729 to 
0.159  
0.207  
MAP − 0.004 − 0.020 to 
0.013  
0.650  
Hypertension 0.207 − 0.315 to 
0.729  
0.434  





0.148 − 0.343 to 
0.638  
0.553 
Recent stroke lesion Age 0.019 − 0.067 to 
0.105  
0.666  





− 2.017 − 3.621 to 
− 0.413  
0.014  
MAP 0.027 − 0.032 to 
0.086  
0.366  
Hypertension 2.195 0.194 to 
4.197  
0.032  





0.774 − 0.965 to 
2.514  
0.380  
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in WM, GM, and WMH (Van De Haar et al., 2016a; Van De Haar et al., 
2016b), though associations did not survive correction for diabetes and 
other non-cardiovascular diseases. Zhang et al also found decreased vp in 
WMH of patients relative to age- and sex-matched controls (Zhang et al., 
2017) in a univariate analysis, but not when adjusted for risk factors. 
These variations in findings may result from differences in patient 
population, sample size, methodology and stage of disease, which may 
skew towards lower/higher disease burdens or be associated with a 
more or less acute effect. Region selection and disease quantification 
methods also differed between studies. While small manually defined 
regions of interest provide consistent sample volume they may be less 
representative and potentially subject to rater bias, while Freesurfer can 
fail in up to 20% of stroke datasets (Liew et al., 2020). Different ap-
proaches to assessing disease burden may affect the degree and signifi-
cance of associations. We found PS; and vp were generally more strongly 
associated with Fazekas score than WMH volume. While Fazekas score 
and WMH volume are highly correlated, each has limitations. Compu-
tational methods may omit subtle hyperintensities (Valdes Hernandez 
et al., 2013), although the method used here is very sensitive to subtle 
WMH. Visual scoring has floor and ceiling effects (although the Fazekas 
score has a wide dynamic range) and may be less sensitive to small 
differences in WMH severity than WMH volume (van Straaten et al., 
2006). Therefore, computational and visual metrics of WMH severity are 
complementary metrics which can provide additional insight. 
4.3. Associations between tracer kinetic parameters and age 
We found PS and vP declined weakly with age in GM, WM and WMH, 
Gd concentration in the vascular input functions and tracer concentra-
tion curves for GM, WM and WMH also tended to be lower across time. 
Peak concentration reflects intravascular contrast (Wardlaw et al., 
2017) and is highly dependent on acquisition time. However, consis-
tently higher Gd concentrations at later timepoints may be due to higher 
vascular surface area in younger patients, potentially contributing to the 
observed decline in PS with age in this population. Specifically, younger 
patients with a stroke and established WMH, required for inclusion, may 
have inherently worse vascular state than an older person with a stroke 
and similar WMH severity. Age can therefore be a major confounder 
when a disease must be present in a study. Several previous studies have 
found older age to be associated with markers of increased permeability 
(Farrall and Wardlaw, 2009; Wardlaw et al., 2003), including CSF: 
plasma albumin ratio (Castellazzi et al., 2020) and DCE-MRI semi- 
quantitative (Wardlaw et al., 2017) approaches. Taheri et al did not find 
a correlation between age and Ki or CSF:plasma albumin ratio in patients 
with suspected vascular cognitive impairment (Taheri et al., 2011). 
Montagne et al found KTrans in the hippocampus increased with age but 
no associations between age and permeability in a restricted sample of 
white matter in the same subjects (Montagne et al., 2015). Increased 
KTrans in the hippocampus and parahippocampal gyrus has also been 
reported in patients with early cognitive dysfunction relative to controls 
and adjusting for age, but found no association with age (Nation et al., 
2019). Several papers compare to age-matched controls or include age 
as a covariate in their statistical analysis but do not report regression 
coefficients for age (Li et al., 2017; Van De Haar et al., 2016a; Van De 
Haar et al., 2016b; Zhang et al., 2019; Zhang et al., 2017). As such, the 
associations between tracer kinetic parameters and age in SVD pop-
ulations have been under explored. In older patients, perforating arte-
rioles and capillaries become sparse with fewer branches resulting in a 
reduced vascular surface area (Bailey et al., 2004), which would be 
consistent with reduced vP. As PS is the product of vascular surface area 
and permeability, reductions in PS with age may be explained by vessel 
density and size changes; indeed this has been proposed as an expla-
nation for the apparent higher values of PS in GM vs. WM (Ostergaard 
et al., 2016; Varatharaj et al., 2019). Such considerations may therefore 
affect the interpretation of PS values, particularly in WMH, where they 
may be less indicative of permeability than decreasing vascular surface 
area. Current techniques do not allow reliable measurement of vessel 
size and density in vivo, indicating an urgent need for further preclinical, 
post-mortem or retinal studies to better account for vessel sparsity and 
surface area. Existing comorbidities also complicate interpretation of 
age-related effects in SVD patients (Wardlaw et al., 2019). 
Fig. 1. Plots of dichotomised Fazekas score (≤3 in pink and ≥4 in blue) against age, permeability surface area (PS), top, and blood plasma volume fraction (vP), 
bottom, in grey matter (GM), white matter (WM) and white matter hyperintensities (WMH). (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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4.4. Associations between tracer kinetic parameters and hypertension 
Patients with hypertension had decreased vP in WM, GM and WMH, 
and increased PS in recent stroke lesions. Hypertension is a SVD risk 
factor (Yakushiji et al., 2014), linked to WMH burden and, via endo-
thelial impairment, BBB dysfunction, particularly when uncontrolled 
(Meissner, 2016). Over time, high blood pressure is thought to lead to 
stiffening of the arteries, reduced vasoreactivity and impaired autor-
egulation of cerebral blood flow (Meissner, 2016). Regional decreases in 
cerebral blood flow are reported in older patients with hypertension 
(Beason-Held et al., 2007) and WMH (Shi et al., 2016). Hypertension 
related vascular changes may therefore contribute to lower vP via re-
ductions in blood flow or potentially underlying vascular changes. 
4.5. Strengths/limitations 
The strengths of this study include the large, well-characterised 
cohort of patients scanned on a single scanner, the largest such sample 
to date, and quantitative measurement of physiological parameters (PS 
and vP) closely following consensus recommendations (Thrippleton 
et al., 2019), adjusted for key covariates. Limitations include the 
methodological shortcomings of existing methods for acquiring and 
measuring BBB permeability in patients in vivo, slightly lower temporal 
resolution and longer acquisition duration than recommended (Thrip-
pleton et al., 2019). Use of DCE-MRI to measure subtle BBB leakage, as 
thought to occur in SVD, remains challenging because of the low-level 
BBB leakage and comparatively large molecular size of Gadolinium 
based contrast agents (Nitta et al., 2003; Shao et al., 2020). Gadolinium 
use also limits inclusion of patients with impaired kidney function. 
While other approaches exist, including multiple flip angle multi-echo 
and diffusion-weighted arterial spin labelling quantification of trans-
endothelial water exchange (Dickie et al., 2020), [68Gd]EDTA positron 
emission tomography (PET) (Schlageter et al., 1987), CSF albumin 
measurement (Janelidze et al., 2017) etc, these also have inherent 
limitations, specifically: the BBB is permeable to water via various 
mechanisms hence water exchange may not reflect pathological leakage, 
and is also very difficult to measure (Dickie et al., 2020); CSF markers do 
not provide regional specificity to BBB permeability and are influenced 
by CSF flow (Janelidze et al., 2017); PET and CT involve exposure to 
ionising radiation. Careful application of tissue-based regions of interest 
helps reduce noise and partial volume effects, however in patients with 
higher WMH burden, the residual volumes of WM and GM may be small 
and subject to greater contamination potentially skewing associations. 
Lastly, while Patlak is currently considered the best of the available 
models for tracer kinetic analysis of low level BBB leakage (Heye et al., 
2016), all such models make assumptions regarding the physiological 
state and real deviations from these may confound the measurements 
and cannot currently be quantified. 
4.6. Future directions 
Further validation and development of existing and novel techniques 
to quantify BBB integrity in-vivo are required to broaden usage and 
provide a basis for further developments (Thrippleton et al., 2019). In 
particular, methodological development is required to account for dif-
ferences in vascular surface area which may effect estimates of PS. A 
surrogate metric relating to surface area, such as vB (Varatharaj et al., 
2019), could alternatively be included as a predictor variable. However, 
validation would be required to determine how representative such 
metrics are of the vascular surface area. In-silico methods are also a 
promising approach to evaluate the influence of different noise sources, 
acquisition, and analysis strategies at minimal cost (Bernal et al., 2021; 
Manning et al., 2021). While promising non-contrast based imaging 
MRI-based techniques, including diffusion-weighted arterial spin label-
ling, require further development, particularly to improve the limited 
SNR in white matter. Lastly, regional analyses may mask local differ-
ences, WMH may vary in their constituent tissue characteristics and 
underlying vascular (dys)function depending on their age and stage of 
evolution. Longitudinal studies at higher magnetic field strengths may 
allow systematic comparisons with structural neuroimaging data to 
investigate how local BBB permeability relates to visible pathologies 
(Clancy et al., 2021). 
4.7. Conclusion 
In conclusion, we have shown quantitative measurement of BBB 
Table 3 
Plasma volume fraction (vP, 10− 2) against age (years), Fazekas score, stroke 
subtype, mean arterial pressure (mmHg), hypertension status, pulse pressure 
(mmHg) and smoking status in each tissue type of interest. (WM = white matter, 
CI = confidence interval, MAP = mean arterial pressure).   
Tissue vP associations using Fazekas score 
Tissue Variable B 
coefficient 
95% CI p-value 
Normal appearing 
WM 
Age − 0.008 − 0.013 to 
− 0.002  
0.008  





0.060 − 0.043 to 
0.163  
0.255  
MAP 0.001 − 0.003 to 
0.005  
0.648  
Hypertension − 0.162 − 0.283 to 
− 0.040  
0.009  










Age − 0.008 − 0.016 to 
0.000  
0.063  
Fazekas score − 0.088 − 0.138 to 




0.078 − 0.069 to 
0.225  
0.295  
MAP 0.001 − 0.004 to 
0.006  
0.718  
Hypertension − 0.172 − 0.346 to 
0.001  
0.051  





− 0.002 − 0.164 to 
0.161  
0.985 
Grey matter Age − 0.007 − 0.014 to 
− 0.001  
0.020  





0.073 − 0.041 to 
0.186  
0.207  
MAP − 0.000 − 0.004 to 
0.004  
0.917  
Hypertension − 0.145 − 0.279 to 
− 0.012  
0.033  





− 0.131 − 0.256 to 
− 0.006  
0.041 
Recent stroke lesion Age − 0.001 − 0.012 to 
0.010  
0.887  





− 0.136 − 0.339 to 
0.068  
0.189  
MAP 0.001 − 0.006 to 
0.009  
0.755  
Hypertension − 0.159 − 0.412 to 
0.095  
0.218  





0.091 − 0.130 to 
0.311  
0.418  
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integrity using tracer kinetic modelling reveals associations between 
microvascular integrity and SVD. To our knowledge our study is the 
largest in which such whole brain measures have been obtained in a 
population with a high prevalence of SVD. The relationship between 
clinically relevant markers of SVD and BBB permeability is complex due 
to the heterogeneity of the condition and methodological challenges. 
Despite this, the emerging associations between BBB impairment and 
clinically relevant parameters indicate that it is an important mecha-
nism for further study to better understand the pathophysiology of SVD 
and as a potential target for development of novel treatments. 
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